GlassScriptPhysician profile
Vanessa Geyer
NPI 1225694888
$1,532.55
in general payments reported to CMS, 2019-2025
23 companies · $271 in 2025
The $271 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $294 · 2022: $350 · 2023: $387 · 2024: $231 · 2025: $271.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $889.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $888.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $211.77 | 2022-2024 | Azstarys |
| Merck Sharp & Dohme LLC | $185.84 | 2021-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Supernus Pharmaceuticals, INC. | $170.89 | 2023-2025 | Qelbree, Qelbree |
| Baxter Healthcare | $117.60 | 2022 | |
| Ironshore Pharmaceuticals INC. | $115.84 | 2021-2024 | Jornay Pm |
| Abbott Laboratories | $108.38 | 2021-2022 | |
| Tris Pharma INC | $97.12 | 2022-2024 | Dyanavel Xr |
| Cranial Technologies, INC | $91.79 | 2021-2025 | Doc Band |
| Pfizer INC. | $58.49 | 2021-2024 | |
| Glaxosmithkline, LLC. | $55.14 | 2021-2024 | Bexsero |
| Lilly USA, LLC | $50.65 | 2022-2023 | Jardiance |
| Adlon Therapeutics L.P. | $36.76 | 2021 | |
| Sanofi Pasteur INC. | $36.38 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.95 | 2021 | |
| Collegium Pharmaceutical, INC. | $21.10 | 2025 | Jornay Pm |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $20.45 | 2024 | |
| Lifescan, INC. | $18.54 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $18.42 | 2024 | Crysvita |
| Sobi, INC | $18.22 | 2021 | |
| Sanofi-Aventis U.S. LLC | $17.67 | 2025 | |
| Seqirus USA INC | $16.85 | 2025 | Flucelvax |
| Alk-Abello, INC | $15.40 | 2025 | Ragwitek, Grastek, Odactra |
| Kowa Pharmaceuticals America, INC. | $15.30 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vanessa Geyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.